Product Images Doxazosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Doxazosin NDC 68788-8422 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Doxazosin Tablets USP 2mg - E046E0B7 F510 4318 9884 034D683864D4 00

Doxazosin Tablets USP 2mg - E046E0B7 F510 4318 9884 034D683864D4 00

Doxazosin Tablets USP 2mg is a generic drug used for treating high blood pressure and is equivalent to Cardura. Each tablet contains doxazosin mesylate, measuring 2mg in power. The drug should be stored within the temperature range of 20°C to 25°C, with an excursion permitted to 15°C to 30°C. The tablets are of capsule shape, white, scored and carry the label APO 094. The drug should be used according to the physician's instructions, and it is essential to keep it away from the reach of children. Important details such as the product number (NDC), expiration date, lot#, and batch# are required for inventory and record-keeping purposes. Federal law restricts the transfer of the drug to the patient for whom it was prescribed.*

doxazosin-structure.jpg - doxazosin structure

doxazosin-structure.jpg - doxazosin structure

figure1.jpg - figure1

figure1.jpg - figure1

This appears to be a table or graph displaying data on the mean change in total symptom score and increase in maximum urinary flow score from baseline, over a duration of treatment in weeks. The asterisks indicate statistical significance, with *p <0.05 meaning the data is significantly different from placebo, and +p <0.05 meaning the data is significantly different from baseline. Doxazosin titration to a maximum of 8 mg is also mentioned.*

table3.jpg - table3

table3.jpg - table3

This is a summary of effectiveness data in placebo-controlled clinical trials for doxazosin in the treatment of BPH (Benign Prostatic Hyperplasia). The data includes the maximum flow rate and symptom score (measured in mL/sec and on a scale of 0-30) and mean baseline change for placebo and doxazosin groups across different titration regimens and study durations. The modified Boyarsky questionnaire (range 7-39) was used in Study 2. The asterisks indicate additional information, such as the number of patients receiving a dose of 8mg doxazosin and the significance of mean change compared to placebo.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.